Despite advances in behavioral health management, managed care persistenently incurs significant costs for members with a diagnosis of substance dependence.
National data based on 20 million commercial plan lives shows that substance-dependent members average $8,290 in annual paid claims, compared to $3,250 for those without substance dependence. Based on 2007 statistics, the federal Healthcare Cost and Utilization Project presents an even worse picture for those with substance dependence as a principal diagnosis. The average length of a hospital stay was five days at a cost of approximately $13,000, with a range of $11,000 to $26,000.
According to the report, examples of related medical conditions included: hypertension, asthma, diabetes, esophageal disorders, anemia and hepatitis. High-utilizing substance dependent (HUSD) members-defined as those with total annual claims greater than $7,500-average $25,500 in annual claims costs. Within the commercial population, the incidence of substance dependence is 1.93%, and approximately 26% of these are HUSD members.
CLAIMS DO NOT TELL ALL
Exacerbating the problem, relatively few members with a substance-dependence diagnosis receive treatment. The National Survey on Drug Use and Health states that only about 10% of individuals who need treatment receive it. Further claims analysis of HUSD members found that only 28% had claims for substance-dependence treatment.
However, there were significant claims incurred under the medical classification for these members. Substance dependence is not a condition that occurs in isolation. Twenty-five percent of individuals with substance dependence also have a serious mental illness, and substance dependence complicates other chronic illnesses. In each case, a comorbid condition in a HUSD member increases costs between 75% and 360%, compared to those without substance dependence.
Mental health, substance abuse and medical health treatment systems have traditionally developed independently and today's treatment approach is fragmented. The absence of a coordinated care continuum results in poor compliance. There is a need for behavioral/medical care integration in the substance dependence and mental health area, as well as a need for accountability of total member healthcare costs rather than compartmentalizing claims into behavioral versus medical costs. The new paradigm must respect the chronic nature of the disease and account for the intensity required to enhance compliance for the substance-dependent individual.
Gary Ingenito, MD, PhD, is a healthcare researcher and scientist with Catasys, a specialty provider of services in the area of substance dependence.
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
How Health Insurers Can Create Remarkable Experiences in a Rapidly Changing Industry
March 22nd 2024The health industry is changing rapidly, and organizations that don’t adapt are going the way of the Model T. By offering new solutions and capabilities, successful organizations are supporting their customers with whole-person, full-journey care.
Read More
High-Deductible Health Plans Linked to Greater Risk of Complications from Diabetes, Study Shows
March 22nd 2024High-deductible health plans are supposed to make patients smarter shoppers for healthcare services. But result reported in JAMA Network Open today add to the evidence that people with chronic conditions such as diabetes may put off care when deductibles are high, increasing the risk of complications and worsening of the disease.
Read More